Week Ending October 4, 2021

Get Tested, Get Cured: Hepatitis C Infections Rising Among 20-39 Year-Olds
“Viral hepatitis is a serious, preventable public health threat that puts people who are infected at increased risk for liver disease, cancer and death.”

Drug Users Testify as MA Lawmakers Weigh Safe Consumption Sites
“On September 27, Massachusetts lawmakers invited members of the public to speak about safe consumption sites (SCS). The state legislature is considering a bill to authorize SCS in any city that wants one. Rising overdose deaths in the state make the deliberations ever more urgent.”

What is the relationship between depression and hepatitis C?
“Depression and hepatitis C are two separate conditions. However, people with hepatitis C may have an increased risk of developing depression.”

Cascade of Care Program Aids in Promoting Treatment for Hepatitis C Patients
“A cascade of care program is aiding Australian people who inject drugs and are also hepatitis C virus (HCV) positive initiate and complete treatment. A team, led by Daisy Gibbs, National Drug and Alcohol Research Centre, UNSW Sydney, identified the ongoing cascade of care plans among Australian patients with HCV who inject drugs and identified the factors associated with engagement at each of the stages.”

Outcomes of Rapid Treatment With Sofosbuvir-Velpatasvir in Patients With Hepatitis C Virus who use Injectable Drugs
“Among patients with hepatitis C virus (HCV) infection with a history of injectable drug use, those who underwent rapid treatment with a 7-day course of sofosbuvir-velpatasvir achieved significantly increased cure rates compared with those treated with usual care, according to research presented at IDWeek, held virtually from September 29 to October 3, 2021.”

Achieving Health Equity in Liver Cancer
“Primary liver cancer is a leading cause of cancer-related illness and death worldwide. It is the sixth most-common cancer and the third most-common cause of death from cancer globally.1 Primary liver cancer includes hepatocellular carcinoma (HCC) (75%-85% of primary liver cancers) and intrahepatic cholangiocarcinoma or bile duct cancer (10%-15% of primary liver cancers).”